Summary
Taurine has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Long COVID / Post-Acute COVID Sequelae (PACVS). No registered clinical trial in this database tests Taurine specifically in Long COVID / Post-Acute COVID Sequelae (PACVS). The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 3 publications for this pair: 2 Cochrane reviews and 1 clinical trial publication. Publication years run from 2021 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Post-Acute COVID/Vaccination Syndrome ranks 675 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous resolution at 12 months: ~50-70% of patients; persistent symptoms at 2 years in 30-50%; severely debilitating long COVID in 10-15% at 1 year without intervention.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 17.0 (trials 0.0, literature 12.0, tier 5, approved bonus 0.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 3 (2 Cochrane reviews, 1 clinical trial publication) |
| Agent type | Supplement |
| Development stage (any indication) | Preclinical |
| Mechanism / class | Metabolic modulation as a therapeutic strategy for post-acute vaccination syndrome (PACVS) · Halma M, Varon J · 2025 |
| Data sources | OSMF Chronic Disease Review |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Taurine to Long COVID / Post-Acute COVID Sequelae (PACVS) in the current OSMF trial extract.
Published literature
- Cochrane review Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysisWang K, Ma CH, Khoramjoo M et al. · BMC infectious diseases · 2026 · PMID 41803812
- Cochrane review Metabolomic characteristics and related pathways in patients with different severity of COVID-19: a systematic review and meta-analysisBi C, He J, Yuan Y et al. · Journal of global health · 2025 · PMID 40019163
- Clinical trial publication The serum amino acid profile in COVID-19Atila A, Alay H, Yaman ME et al. · Amino acids · 2021 · PMID 34605988
Mechanism and notes
Recorded mechanism or class: Metabolic modulation as a therapeutic strategy for post-acute vaccination syndrome (PACVS) · Halma M, Varon J · 2025.
OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Taurine approved for Long COVID / Post-Acute COVID Sequelae (PACVS)?
Taurine has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Long COVID / Post-Acute COVID Sequelae (PACVS). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Taurine in clinical trials for Long COVID / Post-Acute COVID Sequelae (PACVS)?
No registered clinical trial in this database tests Taurine specifically in Long COVID / Post-Acute COVID Sequelae (PACVS). The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Taurine in Long COVID / Post-Acute COVID Sequelae (PACVS)?
Synthesis-level literature links Taurine to Long COVID / Post-Acute COVID Sequelae (PACVS), but no registered trial in this database tests the pair, so the evidence is observational, pooled from other indications, or pre-dates registry practice. OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.